FDA Approved: CIMZIA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for CIMZIA (certolizumab pegol) submitted by UCB, Inc., resulting in an approved amendment to its product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Crohn Disease
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)

Snippet

SUPPL AP for CIMZIA (CERTOLIZUMAB PEGOL)